resTORbio, Inc. (TORC): Price and Financial Metrics
TORC Price/Volume Stats
| Current price | $15.96 | 52-week high | $17.22 |
| Prev. close | $2.37 | 52-week low | $0.86 |
| Day low | $15.47 | Volume | 121,614 |
| Day high | $17.22 | Avg. volume | 1,153,737 |
| 50-day MA | $2.34 | Dividend yield | N/A |
| 200-day MA | $1.72 | Market Cap | 581.81M |
TORC Stock Price Chart Interactive Chart >
resTORbio, Inc. (TORC) Company Bio
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases and conditions in the United States. It is developing TORC1 inhibitor class of pharmaceutical products, including RTB101 and RTB101 with everolimus that are in Phase IIb clinical trial for the treatment of respiratory tract infections; and that have completed Phase I clinical trials for the treatment of heart failure with preserved ejection fraction and autophagy-related neurodegenerative diseases, as well as other infections, such as urinary tract infections. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.
Latest TORC News From Around the Web
Below are the latest news stories about resTORbio Inc that investors may wish to consider to help them evaluate TORC as an investment opportunity.
Adicet Announces Completion of Merger with resTORbio\- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”-MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading on Nasdaq under the symbol “TORC”). The new combined company will operate under the name Adicet Bio, Inc. and will commence trading on the Nasdaq Global Market under the ticker symbol “ACET” on September 16, 2020.Adicet will focus on advancing its pipeline of “off-the-shelf” gamma ... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and INWK Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Adicet Bio Receives $10 Million Product Development Milestone From RegeneronAdicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron. ADI-002 is the first of Adicet Bio's allogeneic off-the-shelf γδ T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and VSLR Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MXIM, INWK, TORCNEW YORK, NY / ACCESSWIRE / July 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following mergers are fair to shareholders. |
TORC Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -74.06% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -82.71% |
Loading social stream, please wait...